Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System.
To assess the utility of Extended Clearance Classification System (ECCS) in understanding absorption, distribution, metabolism, and elimination (ADME) attributes and enabling victim drug-drug interaction (DDI) predictions.



A database of 368 drugs with relevant ADME parameters, main metabolizing enzymes, uptake transporters, efflux transporters, and highest change in exposure (%AUC) in presence of inhibitors was developed using published literature. Drugs were characterized according to ECCS using ionization, molecular weight and estimated permeability.



Analyses suggested that ECCS class 1A drugs are well absorbed and systemic clearance is determined by metabolism mediated by CYP2C, esterases, and UGTs. For class 1B drugs, oral absorption is high and the predominant clearance mechanism is hepatic uptake mediated by OATP transporters. High permeability neutral/basic drugs (class 2) showed high oral absorption, with metabolism mediated generally by CYP3A, CYP2D6 and UGTs as the predominant clearance mechanism. Class 3A/4 drugs showed moderate absorption with dominant renal clearance involving OAT/OCT2 transporters. Class 3B drugs showed low to moderate absorption with hepatic uptake (OATPs) and/or renal clearance as primary clearance mechanisms. The highest DDI risk is typically seen with class 2/1B/3B compounds manifested by inhibition of either CYP metabolism or active hepatic uptake. Class 2 showed a wider range in AUC change likely due to a variety of enzymes involved. DDI risk for class 3A/4 is small and associated with inhibition of renal transporters.



ECCS provides a framework to project ADME profiles and further enables prediction of victim DDI liabilities in drug discovery and development.
Pharmacokinetcis, Dynamics and Metabolism, Pfizer Inc., Cambridge, Massachusetts, USA. Ayman.El-Kattan@pfizer.com.
Ayman F
AF
El-Kattan
Pharmacokinetcis, Dynamics and Metabolism, Pfizer Inc., Groton, Connecticut, USA.
Manthena V
MV
Varma
Pharmacokinetcis, Dynamics and Metabolism, Pfizer Inc., Cambridge, Massachusetts, USA.
Stefan J
SJ
Steyn
Pharmacokinetcis, Dynamics and Metabolism, Pfizer Inc., Cambridge, Massachusetts, USA.
Dennis O
DO
Scott
Pharmacokinetcis, Dynamics and Metabolism, Pfizer Inc., Cambridge, Massachusetts, USA.
Tristan S
TS
Maurer
Clinical Pharmacology, Pfizer Inc., Groton, Connecticut, USA.
Arthur
A
Bergman
D000327:Adsorption; D003198:Computer Simulation; D062126:Databases, Chemical; D055808:Drug Discovery; D004347:Drug Interactions; D006801:Humans; D007477:Ions; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D008954:Models, Biological; D008970:Molecular Weight; D010539:Permeability; D004364:Pharmaceutical Preparations / Q000737:chemistry* / Q000145:classification / Q000378:metabolism
D007477:Ions; D004364:Pharmaceutical Preparations
DDI; active hepatic uptake; clearance mechanism; metabolism; renal elimination